Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Hyaluronidase news
All news on
Hyaluronidase
(also known as
Hyalase
,
Vitrase
,
Amphadase
,
Hylenex
,
rHuPH20
,
recombinant human hyaluronidase PH20
, and
ENHANZE
): plants, production capacities, investments and involved companies.
24 March 2026
WuXi Biologics posts record 2025 results
2025 revenue +16.7% to RMB21.8bn; gross margin +500bps to 46%; EBITDA +38%; net profit +45%; 209 new integrated projects; backlog US$23.7bn; bi-/multi-specifics >120% growth
12 March 2026
WuXi Biologics and Earendil Labs Partner to Develop Antibodies and ADCs
The collaboration aims to speed up development and manufacturing of bispecific/multispecific antibodies and ADCs for autoimmune diseases and cancer, leveraging AI and advanced biologics expertise.
19 February 2026
Johnson & Johnson's Rybrevant Faspro™ Shows 56% Response Rate in First-Line Head and Neck Cancer
The OrigAMI-4 study shows amivantamab with immunotherapy offers durable antitumor activity in recurrent/metastatic head and neck cancer, improving outcomes over current treatments.
17 February 2026
Genmab Releases 2025 Annual Report
The report highlights 2025 achievements, financials, and 2026 outlook, including revenue growth, strategic acquisitions, and regulatory approvals.
11 February 2026
Merck's KEYTRUDA and KEYTRUDA QLEX Approved for PD-L1+ Platinum-Resistant Ovarian Cancer
FDA approves KEYTRUDA regimens for platinum-resistant ovarian cancer, showing reduced disease progression and death risk in trials.
8 January 2026
Takeda and Halozyme Collaborate on Vedolizumab
The partnership aims to enhance vedolizumab delivery for IBD treatment, improving patient care and expanding access with ENHANZE technology.
Who will be producing Hyaluronidase in the future?
Find out with
chemXplore Alpha
Learn more
17 December 2025
Johnson & Johnson's RYBREVANT FASPRO™ Gains FDA Approval for Faster NSCLC Treatment
FDA approves RYBREVANT FASPRO™ for EGFR-mutated NSCLC, offering faster, subcutaneous administration with fewer side effects compared to IV delivery.
15 December 2025
Janssen's TECVAYLI® and DARZALEX FASPRO® Join FDA's Priority Voucher Program
TECVAYLI® and DARZALEX FASPRO® show significant survival benefits in multiple myeloma, gaining FDA Breakthrough Therapy Designation and Real-Time Oncology Review.
6 November 2025
Johnson & Johnson's DARZALEX FASPRO®: First FDA-Approved Treatment for High-Risk Smoldering Multiple Myeloma
DARZALEX FASPRO® reduces progression risk to active multiple myeloma by 51% in high-risk patients, marking a shift in treatment strategy.
19 October 2025
Johnson & Johnson's Subcutaneous Amivantamab Shows 45% Response Rate in Head and Neck Cancer
Subcutaneous amivantamab offers rapid, durable responses in head and neck cancer, with 82% tumor shrinkage and a median response duration of 7.2 months.
14 October 2025
Genmab Reports Q3 2025 DARZALEX Sales of $3.67 Billion
Genmab earns royalties from DARZALEX sales, with $2.09B in the U.S. and $1.58B globally. The company focuses on innovative antibody therapeutics for cancer and serious diseases.
19 September 2025
Merck Gains EU CHMP Support for KEYTRUDA SC and New Head and Neck Cancer Use
CHMP backs KEYTRUDA SC for all EU adult indications and a new use in LA-HNSCC. Awaiting European Commission's final decision.
